What is Wedbush’s Forecast for Ardelyx FY2026 Earnings?

Ardelyx, Inc. (NASDAQ:ARDX) – Investment analysts at Wedbush dropped their FY2026 earnings per share estimates for Ardelyx in a report issued on Friday, November 1st. Wedbush analyst L. Chico now anticipates that the biopharmaceutical company will post earnings of $0.06 per share for the year, down from their prior estimate of $0.08. Wedbush currently has a “Outperform” rating and a $11.00 price target on the stock. The consensus estimate for Ardelyx’s current full-year earnings is ($0.25) per share. Wedbush also issued estimates for Ardelyx’s FY2027 earnings at $0.38 EPS and FY2028 earnings at $0.66 EPS.

Other equities analysts have also recently issued reports about the stock. Citigroup decreased their target price on shares of Ardelyx from $12.00 to $10.00 and set a “buy” rating for the company in a research note on Monday. HC Wainwright reissued a “buy” rating and issued a $11.00 price objective on shares of Ardelyx in a research report on Friday, November 1st. Finally, StockNews.com raised shares of Ardelyx from a “sell” rating to a “hold” rating in a report on Wednesday, July 31st. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Ardelyx has an average rating of “Moderate Buy” and a consensus target price of $11.33.

Ardelyx Stock Down 2.9 %

NASDAQ:ARDX opened at $5.72 on Monday. Ardelyx has a twelve month low of $3.43 and a twelve month high of $10.13. The firm has a market capitalization of $1.35 billion, a price-to-earnings ratio of -19.07 and a beta of 0.92. The company has a quick ratio of 3.87, a current ratio of 4.03 and a debt-to-equity ratio of 0.64. The stock’s 50 day moving average price is $6.05 and its two-hundred day moving average price is $6.31.

Insider Buying and Selling

In other Ardelyx news, insider David P. Rosenbaum sold 20,507 shares of the stock in a transaction dated Tuesday, August 20th. The shares were sold at an average price of $6.00, for a total value of $123,042.00. Following the transaction, the insider now directly owns 158,502 shares of the company’s stock, valued at $951,012. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Ardelyx news, insider David P. Rosenbaum sold 20,507 shares of the stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $6.00, for a total transaction of $123,042.00. Following the transaction, the insider now owns 158,502 shares in the company, valued at $951,012. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider David P. Rosenbaum sold 20,000 shares of the business’s stock in a transaction dated Friday, August 16th. The shares were sold at an average price of $5.94, for a total transaction of $118,800.00. Following the completion of the sale, the insider now directly owns 356,479 shares of the company’s stock, valued at approximately $2,117,485.26. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 212,126 shares of company stock valued at $1,298,963. Company insiders own 5.90% of the company’s stock.

Institutional Investors Weigh In On Ardelyx

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Nisa Investment Advisors LLC grew its position in Ardelyx by 1,026.3% during the second quarter. Nisa Investment Advisors LLC now owns 3,548 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 3,233 shares in the last quarter. Redwood Wealth Management Group LLC bought a new position in shares of Ardelyx in the second quarter worth $62,000. Coastal Bridge Advisors LLC acquired a new position in Ardelyx in the second quarter valued at about $74,000. Helen Stephens Group LLC bought a new stake in Ardelyx during the third quarter worth about $76,000. Finally, Paloma Partners Management Co acquired a new stake in Ardelyx during the first quarter worth about $86,000. 58.92% of the stock is currently owned by institutional investors and hedge funds.

Ardelyx Company Profile

Ardelyx, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company’s lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation.